explore -WSS

explore

author：explore 2025-09-03 05:38:47 - browse：99678

Peter Marks, Director of the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA), testifies during a Senate Health, Education, Labor and Pensions Committee hearing to discuss the on-going federal response to Covid-19 on May 11, 2021 at the US Capitol in Washington, DC. — FDA's Peter Marks JIM LO SCALZO/POOL/AFP via Getty Images

WASHINGTON — The Food and Drug Administration needs dozens more reviewers if it wants its so-called Operation Warp Speed for rare disease therapies to take off, the agency’s biologics chief said Monday.

The administration launched the rare disease pilot program, dubbed START and modeled after the record race for a Covid-19 vaccine, this September. Peter Marks, head of the Center for Biologics Evaluation and Research, has spearheaded both initiatives.

“If we were really to expand this significantly, [it] would require us to get dozens of additional staff members,” Marks told listeners during a gene therapy discussion hosted by the Alliance for a Stronger FDA. “One could say ‘Oh my goodness, he’s asking for more headcount again.’ Well, if this really does reduce the time to development by 25 to 50% … it probably won’t take industry too long to do a net present value calculation to say ‘Oh, it’s worth making sure that they have their extra 20 or 30 or 40 reviewers.’”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Biden outlines 'new path' to provide student loan relief after Supreme Court rejection
Next article： STAT letters to the editor on burnt

leisure time

WSS

STAT letters to the editor on burnt

Teach medical students about patients with intellectual disabilities

Medicare drug price negotiation hasn't dried up venture capital

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Pfizer plans to depart BIO

Why sickle cell disease is getting the first CRISPR treatment

entertainment

explore

focus

Walensky prepares to leave CDC — and Congress — behind

Pharma patents targeted by Biden in move to slash drug prices

Medical leaders decry Supreme Court decision on affirmative action

SNAP should offer more nutrition education

Virginia high school admissions case could be legal follow

Supreme Court wrestles with OxyContin maker's bankruptcy deal

In Memoriam: Notable people who died in 2023

Hospitals owned by private equity see complications spike 25%

Continuity nursing helped my family in our darkest PICU moments

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

entertainment

Patients' immediate access to test results puts radiologists in a bind

Can sheer will power keep patients alive in their dying hours?

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Teach medical students about patients with intellectual disabilities

HCA sued by state AG for quality issues at Mission Health

CMS should re

entertainment

leisure time

entertainment

knowledge